OP0223 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-PSA-2): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL
Mark C. Genovese, Apinya Lertratanakul, J. Anderson, Kim Papp, William Tillett, Filip Van den Bosch, Shigeyoshi Tsuji, Eva Dokoupilová, M. Keiserman, X. Wang, Sheng Zhong, Patrick Zueger, Aileen L. Pangan, Philip J. Mease
Topics & Concepts
MedicinePsoriatic arthritisRheumatoid arthritisPsoriasisInternal medicineClinical endpointAdverse effectCertolizumab pegolPlaceboRandomized controlled trialPsoriasis Area and Severity IndexDermatologyAdalimumabPathologyAlternative medicineRheumatoid Arthritis Research and TherapiesChronic Lymphocytic Leukemia ResearchAutoimmune and Inflammatory Disorders Research